UNSPSC 51313503: Bepiastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H17N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35QK773Y96, chemically known as 6-(2-(dimethylamino)ethyl)pyrido(2,3-b)(1,5)benzothiazepin-5(6h)-one but generally known as bepiastine, which bears US NIH Compound Identifier 185456. European Medicines Agency schedules Bepiastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05777MIG.

UNSPSC 51313503 Bepiastine is a Commodity code that designates a specific pharmaceutical antihistamine product, but recent state and local solicitations using this code do not involve bepiastine procurement. Instead, the code appears in three recent opportunities spanning naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products — none of which are bepiastine compounds. The mismatch between the code's nominal scope and actual procurement activity suggests the code sees little relevant recent demand in the state and local market.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (noting the date discrepancy in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs, with responses due the same day. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across state and local government facilities including Oregon, with a proposal deadline of March 26, 2026. Activity under this code extends across Florida, Texas, and the upper Midwest, but the lack of bepiastine-specific opportunities indicates the code is either misapplied to pharmaceutical procurements generally or underutilized in current state and local markets.